15 Jul 2013
Metformin is an antidiabetic drug, frequently prescribed to patients with type 2 diabetes mellitus (T2DM), obesity, insulin resistance, hyperinsulinaemia. Recently, a few studies revealed possible effects of metformin treatment on thyroid-related characteristics, although no study on humans has investigated the effects of metformin on the association between T2DM and thyroid volume. Therefore, Ittermann et al investigated these effects in a population-based cohort study.
Their study demonstrates a significant association between T2DM and thyroid volume in women not treated with metformin. The study also shows an inhibitory effect of metformin on prevalent and incident goitre. Anti-goitrogenous effects of metformin add to the general benefits of metformin treatment in T2DM. This is of particular relevance for populations from regions with current or former iodine deficiency, where goitre is highly prevalent.
Read the full article at Ittermann et al (2013) European Journal of Endocrinology 169; 9-15; DOI: 10.1530/EJE-13-0101.
New Awards Committee Chair
29 Jan 2025
Society for Endocrinology endorses landmark guidelines for childhood pituitary tumour care
29 Jan 2025
Announcing the Winners of the SfE Emerging Researcher Lectures 2025
23 Jan 2025
Congratulations to the awardees of our third round of 2024 grants
22 Jan 2025